What is a stock summary page? Click here for an overview.
Business Description
Royalty Pharma PLC
NAICS : 541714
SIC : 2833
ISIN : GB00BMVP7Y09
Share Class Description:
RPRX: Class ACompare
Compare
Traded in other countries / regions
RPRX.USARPRX.MexicoRPD.Germany Index Membership
Russell 1000Russell 3000 IPO Date
2020-06-16Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.23 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 1.1 | |||||
| Debt-to-EBITDA | 4.89 | |||||
| Interest Coverage | 5.73 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.68 | |||||
| Beneish M-Score | -2.88 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -11.6 | |||||
| 3-Year EBITDA Growth Rate | -8.7 | |||||
| 3-Year EPS without NRI Growth Rate | -0.5 | |||||
| 3-Year FCF Growth Rate | -1.4 | |||||
| 3-Year Book Growth Rate | 5.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 50.07 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 13.82 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.11 | |||||
| 9-Day RSI | 32.67 | |||||
| 14-Day RSI | 37.24 | |||||
| 3-1 Month Momentum % | 28.95 | |||||
| 6-1 Month Momentum % | 20.07 | |||||
| 12-1 Month Momentum % | 16.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.44 | |||||
| Quick Ratio | 1.44 | |||||
| Cash Ratio | 1.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.75 | |||||
| Dividend Payout Ratio | 0.57 | |||||
| 3-Year Dividend Growth Rate | 7.3 | |||||
| Forward Dividend Yield % | 2.87 | |||||
| 5-Year Yield-on-Cost % | 2.75 | |||||
| 3-Year Average Share Buyback Ratio | -1 | |||||
| Shareholder Yield % | -0.09 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 57.1 | |||||
| Net Margin % | 37.95 | |||||
| FCF Margin % | 122.33 | |||||
| ROE % | 12.89 | |||||
| ROA % | 4.97 | |||||
| ROIC % | 8.11 | |||||
| 3-Year ROIIC % | -4.85 | |||||
| ROCE % | 9.32 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.25 | |||||
| Forward PE Ratio | 6.66 | |||||
| PE Ratio without NRI | 20.94 | |||||
| PS Ratio | 8.11 | |||||
| PB Ratio | 2 | |||||
| Price-to-Tangible-Book | 2 | |||||
| Price-to-Free-Cash-Flow | 6.64 | |||||
| Price-to-Operating-Cash-Flow | 6.64 | |||||
| EV-to-EBIT | 14.78 | |||||
| EV-to-Forward-EBIT | 9.31 | |||||
| EV-to-EBITDA | 14.78 | |||||
| EV-to-Forward-EBITDA | 9.31 | |||||
| EV-to-Revenue | 10.16 | |||||
| EV-to-Forward-Revenue | 7.28 | |||||
| EV-to-FCF | 8.31 | |||||
| Price-to-GF-Value | 0.97 | |||||
| Price-to-Projected-FCF | 0.74 | |||||
| Price-to-Graham-Number | 1.36 | |||||
| Earnings Yield (Greenblatt) % | 6.77 | |||||
| FCF Yield % | 20.54 | |||||
| Forward Rate of Return (Yacktman) % | -15.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RPRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Royalty Pharma PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,263.576 | ||
| EPS (TTM) ($) | 1.803 | ||
| Beta | 0.42 | ||
| 3-Year Sharpe Ratio | -0.3 | ||
| 3-Year Sortino Ratio | -0.47 | ||
| Volatility % | 30.73 | ||
| 14-Day RSI | 37.24 | ||
| 14-Day ATR ($) | 0.787475 | ||
| 20-Day SMA ($) | 32.456 | ||
| 12-1 Month Momentum % | 16.02 | ||
| 52-Week Range ($) | 24.05 - 34.2 | ||
| Shares Outstanding (Mil) | 433.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Royalty Pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Royalty Pharma PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Royalty Pharma PLC Frequently Asked Questions
What is Royalty Pharma PLC(RPRX)'s stock price today?
The current price of RPRX is $31.12. The 52 week high of RPRX is $34.20 and 52 week low is $24.05.
When is next earnings date of Royalty Pharma PLC(RPRX)?
The next earnings date of Royalty Pharma PLC(RPRX) is 2025-05-09 Est..
Does Royalty Pharma PLC(RPRX) pay dividends? If so, how much?
The Dividend Yield %  of Royalty Pharma PLC(RPRX) is 2.75% (As of Today), Highest Dividend Payout Ratio of Royalty Pharma PLC(RPRX) was 0.57. The lowest was 0.33. And the median was 0.42. The  Forward Dividend Yield % of Royalty Pharma PLC(RPRX) is 2.87%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers